DCX and nasopharyngeal carcinoma: On day 7 post-NPC administration, the number of proliferating cells labeled with BrdU and co-localized with DCX, an immature neuronal marker, was significantly increased in the SVZ of the NPC-treated group compared to that in saline-treated group (Figures 3B, C, saline: 1 ± 0.69, NPC: 1.80 ± 0.36, p<0.05).